TB Guidelines



Treatment Guidelines
 Title Format Date Published
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022. MMWR Morb Mortal Wkly Rep, 2022 2/24/2022
Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease 2/2/2022
MMWR /Medscape free CE credit on the updated 2020 latent TB infection treatment guidelines.external icon
Registration may be required.
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
MMWR Recomm Rep 2020; 69(No. RR-1): 1-11.
PDFpdf icon (337 KB) 2/20/2020
Treatment of Drug-Resistant Tuberculosis
American Journal of Respiratory and Critical Care Medicine, 2019
Full Guidelinesexternal icon
Executive Summary
PDFpdf icon  (731 KB)Full Guidelines
PDFpdf icon (1 MB)
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
MMWR 2018;67:723-726
PDFpdf icon
(94 KB)
Treatment of Drug-Susceptible Tuberculosis
Executive Summaryexternal icon
Full Guidelinesexternal icon
Clinical Infectious Disease 2016
PDFpdf icon
(1 MB)
Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis
MMWR  2013;62 (No. 9)
PDFpdf icon
(411 KB)
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis
June 2013
PDFpdf icon
(492 KB)
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC
MMWR  2005; 54 (No. RR-15, 1-37)
PDFpdf icon
(544 KB)
Treating Opportunistic Infections Among HIV-Exposed and Infected Children
MMWR 2004; 53 (RR14)
PDFpdf icon
(742 KB)
Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor – Alpha – California, 2002–2003
MMWR  2004; 53 (No. 30)
PDFpdf icon
(325 KB)
Notice to Readers: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors
MMWR  2004; 53 (No. 2)
PDFpdf iconpdf icon
(349 KB)
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection
MMWR  2003; 52 (No. 31).
PDFpdf icon
(587 MB)